Deciding on a GLP-1 isn't about BMI alone. It depends on your degree of adiposity and comorbidities, what you've already tried, your goals, contraindications (such as medullary thyroid cancer history or pregnancy), your eating behaviour, cost and access, and your long-term plan. This tool walks through those factors so you can have an informed conversation — it is education, not a prescription.
Decision tool — education, not a verdict. This page surfaces the factors that actually drive the decision and ends in "considerations to discuss with a clinician." It never outputs "you need Ozempic." It stores nothing.
Read this first
GLP-1 and dual-incretin medicines (semaglutide, tirzepatide) are genuinely effective for many people — and they are also over-hyped, sometimes inappropriately prescribed, and not right for everyone. Both things are true. → GLP-1 & Incretin Medications hub
The stepper — eight factors that actually drive the decision
(On build: render as the shared decision-tool stepper component. Each step surfaces considerations and links to the evidence behind it. No step produces a "yes/no" verdict; the output is a personalized list of considerations to discuss.)
Step 1 · Adiposity and comorbidities — "is there a medical reason?"
The starting point isn't a number on the scale; it's whether excess adiposity is affecting your health. Clinicians generally consider anti-obesity pharmacotherapy for people with obesity, or with overweight plus a weight-related condition (type 2 diabetes or prediabetes, hypertension, dyslipidaemia, fatty liver, sleep apnea, established cardiovascular disease).
- The stronger the comorbidity burden, the more a medication's benefits (beyond weight) matter — e.g., semaglutide's ~20% reduction in major cardiovascular events in people with established CVD and overweight/obesity without diabetes (SELECT), or tirzepatide's OSA approval. (Grade A 🟢)
- "I just want to lose a few pounds for an event" is a different question from "excess weight is harming my metabolic health." → What Is Obesity?
Consideration surfaced: What weight-related conditions do I have, and could a GLP-1 help those specifically — not just the scale?
Step 2 · What you've already tried
Medication is not a confession of failure, and lifestyle is not "the thing you do before real treatment." But your history matters: what nutrition, activity, sleep and behavioural approaches you've genuinely tried, for how long, and what happened. → The W8Experts Clinical Approach
- Obesity is biologically defended; regain after lifestyle change is common and not a willpower failure. → Why Weight Is So Hard to Lose
- Medication works best alongside nutrition and resistance training, not instead of them. → Nutrition · Exercise & Muscle
Consideration surfaced: What have I actually tried, and is the plan to combine medication with lifestyle rather than replace it?
Step 3 · Your goals — what is the actual target?
The goal is rarely "the scale." It might be diabetes prevention or remission, cardiovascular-risk reduction, liver-fibrosis stabilization, sleep apnea, fertility (PCOS), mobility, or quality of life. Different goals point to different drugs, doses and success measures.
- If the goal is CV-risk reduction with established disease, that evidence favours specific agents. If it's OSA, tirzepatide has the indication. If it's MASH with F2–F3 fibrosis, semaglutide 2.4 mg is approved.
Consideration surfaced: What's my real goal, and which outcome (not just weight) would tell me it's working?
Step 4 · Contraindications and cautions — the hard stops
Some factors are genuine reasons not to take these drugs, or to be cautious. These are non-negotiable to review with a clinician:
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 — a boxed-warning contraindication for GLP-1/incretin agents. (Grade A 🟢)
- History of pancreatitis — caution; individualized.
- Pregnancy, or trying to conceive — avoid; some agents should be stopped well before conception given a long half-life (about two months for semaglutide). → see Step 6.
- Prior severe reaction, certain gallbladder or gastrointestinal conditions, gastroparesis — individualized cautions. → GLP-1 Side Effects
Consideration surfaced: Do I have any of these? A single "yes" (e.g., MTC/MEN2) can take these drugs off the table.
Step 5 · Eating behaviour
How you eat shapes both suitability and safety. GLP-1s reduce appetite and "food noise," which many people find profound — but they are not a treatment for an eating disorder.
- If binge-eating disorder, a restrictive-eating history, or another eating disorder is present, that needs its own assessment and care; medication may still have a role but shouldn't replace psychological treatment. (Grade B 🟡)
- Reduced appetite makes adequate protein and nutrition more important, not less. → GLP-1 & Muscle Loss
Consideration surfaced: Is there a disordered-eating pattern that should be evaluated and supported first or alongside?
Step 6 · Pregnancy plans
A distinct and important branch. GLP-1/incretin agents are avoided in pregnancy, and if you might conceive:
- Plan to stop before conception (about two months ahead for semaglutide given its half-life). (Grade A 🟢)
- Tirzepatide has a labelled oral-contraceptive interaction — a backup or non-oral contraceptive method is advised for about four weeks when starting or increasing the dose. (Grade A 🟢) → Tirzepatide
- For someone conceiving soon (e.g., some PCOS scenarios), the plan often focuses elsewhere entirely.
Consideration surfaced: Am I pregnant, breastfeeding, or planning pregnancy — and is my contraception adequate?
Step 7 · Access and cost
An honest factor, not an afterthought. These medications are expensive, coverage varies, and stopping usually leads to regain — so access has to be sustainable, not just a one-time start.
- If cost or coverage will force stopping in a few months, that changes the calculus (and makes the "compounded shortcut" tempting — with its own safety and quality concerns). (Grade B 🟡)
- Building a plan you can actually sustain beats starting one you'll be forced to abandon. → Weight Regain & Maintenance
Consideration surfaced: Can I realistically access and afford this long enough to benefit — and what's the plan if I can't?
Step 8 · Long-term strategy
Obesity behaves like a chronic condition. These drugs work while taken; stopping predictably leads to regain (STEP 1 extension: ~two-thirds of lost weight regained within ~1 year off drug). So the real question isn't "should I start" but "what's the long-term plan."
- Are you prepared for ongoing therapy, or a deliberate maintenance strategy? → Weight Regain
- Is surgery a better fit for your degree of obesity and goals? Medication and surgery aren't rivals so much as different tools.
Consideration surfaced: What's my multi-year plan — and how will I preserve muscle and maintain results?
What the output looks like
There is deliberately no "you need Ozempic" result. A medication is chosen (or not) by you and a clinician, weighing all of this together.
SIGNATURE — "What the evidence says: choosing a GLP-1"
- What we know: GLP-1/incretin agents produce substantial average weight loss and, for specific agents and populations, real outcome benefits (CV events, OSA, MASH). Contraindications (MTC/MEN2, pregnancy) are well defined.
- What we think: The decision should be driven by comorbidities, goals, contraindications, eating behaviour, pregnancy plans and sustainable access — not by BMI or marketing alone.
- What we don't know: Very long-term outcomes for some newer agents, and the best individual match among expanding options.
- What patients should do: Use this tool to prepare, then decide with a clinician. No online tool should hand you a prescription. → Request an appointment
Questions patients ask
Will this tool tell me if I should take Ozempic?
No — deliberately. It shows you the factors a clinician weighs and produces a list of considerations to discuss, not a verdict or a drug name. A prescription is a clinical decision, not a quiz result. Grade A 🟢
Do I qualify for a GLP-1 if I don't have diabetes?
You can — these agents are approved for chronic weight management in obesity, or overweight with a weight-related condition, independent of diabetes. Whether it's right for you depends on the factors in this tool. Grade A 🟢 → Semaglutide
What would rule me out?
A personal or family history of medullary thyroid cancer or MEN2 is a boxed-warning contraindication; pregnancy or planned pregnancy means avoiding these drugs; a history of pancreatitis and certain GI conditions are cautions. Review these with a clinician. Grade A 🟢 → GLP-1 Side Effects
Can I take a GLP-1 if I'm trying to get pregnant?
No. GLP-1/incretin agents are avoided in pregnancy and should be stopped before conception — about two months ahead for semaglutide. Tirzepatide also has an oral-contraceptive interaction to plan around. Grade A 🟢 → Tirzepatide
Do I have to take it forever?
Often, to keep the benefit — obesity behaves like a chronic condition, and stopping usually leads to regain (about two-thirds of lost weight within a year in trials). Some people transition to a maintenance strategy, but there's rarely a clean "course and done." Grade A 🟢 → Weight Regain
Is a GLP-1 better than surgery?
Neither is universally better. Surgery gives larger, more durable average loss and strong diabetes remission but is a procedure with lifelong follow-up; GLP-1s avoid surgery but need ongoing use. The right choice depends on your degree of obesity, comorbidities and goals. Grade A 🟢 → Bariatric Surgery
Should I use a GLP-1 if I have binge-eating disorder?
Possibly, but not as a substitute for treating the disorder. Binge-eating disorder needs its own psychological (and sometimes pharmacological) care; a GLP-1 may have a role alongside it, evaluated carefully. Grade B 🟡 → Mental Health & Obesity
Will a GLP-1 cost me a lot, and does that matter to the decision?
It can, and yes it matters. Because stopping leads to regain, sustainable access is part of the decision — not an afterthought. If cost will force stopping soon, that's worth planning for upfront. Grade B 🟡 → Compounded GLP-1s
Which is right for me — semaglutide or tirzepatide?
That's a clinician conversation. On average tirzepatide produced greater weight loss head-to-head, but the best choice depends on your goals, comorbidities (OSA, CV disease, MASH), tolerability and access — not the average alone. Grade A 🟢 → Semaglutide vs Tirzepatide
Will taking a GLP-1 cost me muscle?
Some lean mass is lost with any substantial weight loss. What protects muscle and function is adequate protein and resistance training — plan those in from the start rather than treating them as optional. Grade B 🟡 → GLP-1 & Muscle Loss
KEEP READING
- GLP-1 & Incretin Medications — the full hub behind every branch of this tool.
- Semaglutide vs Tirzepatide — how the two leading options compare.
- GLP-1 Side Effects — the tolerability and safety picture.
- Weight Regain & Maintenance — why the long-term plan matters most.
- Do I Have Fatty Liver? — the companion liver-risk tool.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: STEP and SURMOUNT programmes; SELECT; SURMOUNT-OSA; FDA labelling (boxed warning MTC/MEN2; pregnancy; tirzepatide oral-contraceptive interaction); AACE/obesity-medicine guidance. Educational only; not a prescription and not individualized medical advice.
